Abstract: Breast cancer is one of the major challenges for women's health. However, the role and mechanisms of interleukins (ILs) on the progression of breast cancer are not well illustrated. Our present study revealed that the expressions of IL-6 and IL-8 were significantly increased in oestrogen receptor-negative (ERÀ) breast cancer cells. Increased expression of IL-6 was observed in 83.9% (26/31) ERÀ breast cancer tissues as compared with their matched adjacent normal tissues. In vitro studies indicated that IL-6 can significantly promote the migration and invasion of ERÀ breast cancer cells via increasing the dephosphorylation, nuclear translocation and transcriptional activities of YAP in breast cancer cells. Knockdown of YAP can attenuate IL-6-induced migration and invasion of cancer cells, suggesting that YAP plays an essential role in IL-6-induced malignancy of breast cancer cells. Furthermore, IL-6 treatment also decreased the phosphorylation of LATS1/2. The knockdown of LATS1/2 synergistically suppressed si-IL-6-induced deactivation of YAP. Targeted inhibition of IL-6/YAP can significantly suppress the invasion of ERÀ breast cancer cells. Collectively, our study revealed that IL-6 can trigger the malignancy of breast cancer cells via activation of YAP signals. Targeted inhibition of IL-6/YAP might be a novel therapeutic approach for the treatment of ERÀ breast cancer.
As one of the biggest challenges for women's health, the 5-year survival rate of breast cancer patients with distant metastases is still less than 25% [1] . Oestrogenic signals are essential for tumorigenesis and progression of breast cancer [2] . According to the expression of oestrogen receptor a, breast cancer can be divided into oestrogen receptor-positive (ER+) or ER-negative (ERÀ) subtypes. ER-breast cancer is not susceptible to endocrine therapy [3] . In addition, ERÀ breast cancer cells are more aggressive and easily to metastasis [4] . Therefore, patients with ERÀ breast cancer have higher rates of recurrence, worse prognosis and shorter survival rates than ER+ breast cancers [5] . It was reported that more than 30% breast cancer is ERÀ breast cancer [6] . The characterization of risk factors and mechanisms involved in the progression of ERÀ breast cancer will be of great help for the clinical therapy and drug development.
Cytokines secreted by cancer cells or tumour microenvironment can play an important role during cancer progression via regulation of cell proliferation, migration and angiogenesis [7] . Interleukins (ILs) are a group of cytokines including both proinflammatory ILs such as IL-2, IL-6, IL-8, IL-15 and IL-17, and anti-inflammatory ILs include IL-4 and IL-10 [8] . ILs have been linked to the progression of ERÀ breast cancer such as inflammatory pathways and angiogenesis [9, 10] . This is particularly true for IL1B, IL6, IL8 and IL10 [11, 12] . For example, IL-6 and IL-8 were overexpressed in ERÀ breast cancer cells and correlated with the poor prognosis of patients with breast cancer [11] . IL-6 can induce tamoxifen resistance in luminal breast cancer [13] and promote the growth and aggressiveness of breast cancer cells [10] . However, the detailed mechanisms responsible for IL-induced progression of breast cancer are still far from well documented.
Our present study examined the expression of selected ILs in ERÀ breast cancer cell lines and human tissues and found that the expressions of IL-6 and IL-8 were significantly increased. Functional studies revealed that IL-6 triggered the migration and invasion of ERÀ breast cancer cells. YAP, one of the key factors of Hippo signals, was essential for IL-6-induced migration and invasion of ERÀ breast cancer cells.
(MMP2), p-YAP, YAP, H2A, p-LATS1 (Ser909), LATS1, p-MST1/2 (Thr183/Thr180), IL-6 and GAPDH were purchased from Cell Signaling Technology Inc. (Beverly, MA, USA). Horseradish peroxidase-conjugated secondary antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Inhibitors for YAP (verteporfin) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Human recombinant IL-6 and IL-8 proteins were purchased from R&D Systems. All inhibitors were solubilized in dimethyl sulfoxide (DMSO) with the final DMSO concentrations less than 0.5% (v/v).
Quantitative real-time PCR (qRT-PCR). To analyse the mRNA expression in treated cells, the total RNAs were extracted by use of TRIZOL and generated to first-strand cDNA by use of 500 ng of total RNA and All-in-One -GCT  TTG GTT CCA TTC TGC CAG TG-3 0 . GPADH was used as reference gene for normalization.
Breast cancer tissue collection. To investigate the expression of IL-6, the tumour tissues and matched adjacent normal tissues of 31 ERÀ breast cancer patients histologically confirmed were collected under the permission of Ethical Committee in our hospital from July 2014 to January 2017. The samples were stored at À80°C immediately after surgery. The RNAs of both tumour and adjacent tissues were extracted by use of TRIZOL to analyse the expression the mRNA of IL-6. The demographic and clinical features of breast cancer patients are summarized in table 1.
Cell proliferation test. Cell proliferation was tested by use of CCK-8 kit (Dojindo Molecular Technologies, Gaithersburg, MD, USA) according to the instructions of the manufacturer. Briefly, cells treated with IL-6 or IL-8 were seeded in 96-well plates (eight wells each group) at a density of 1 9 10 5 cells per well. After treatment for the indicated times, cells were added 10 ll of CCK-8 solution and incubated for 2 hr before the measurement of absorbance at 450 nm using a microplate reader. Control cells treated with DMEM were taken as 100% viability.
In vitro migration and invasion assays. Effects of IL-6 on the migration and invasion of ERÀ breast cancer cells were evaluated by use of wound healing assay and trans-well assay according to the previous study [14] , respectively. For wound healing assay, cells at 80-90% confluence were scratched by use of a 100-ll tip after the cells formed a confluent monolayer and were then further treated with or without IL-6. The closure of scratch was analysed as indicated times. For in vitro invasion assay, Matrigel-coated 24-well trans-well chambers were used with the upper chamber without FBS while the bottom chamber was filled with medium containing 10% FBS. For analysis, the migration and invasion ability were calculated by counting the stained cells and analysing them statistically.
Western blot analysis. The IL-6-regulated protein expression was checked by Western blot analysis. After lysis, 20 lg total proteins of each group were separated by 10% SDS-polyacrylamide gel electrophoresis and transferred to Polyvinylidene Fluoride (PVDF) membrane (Pall Inc., East Hills, NY, USA). The membrane was blocked by 5% non-fat milk for 1 hr at room temperature and incubated with primary antibody overnight at 4°C. After washing, membranes were incubated with the horseradish peroxidase-conjugated secondary antibody and stained with enhanced chemiluminescence solution. GAPDH was used as the loading control. All Western blot analyses were replicated three times. The most representative blot was showed, and the average values of densitometric analysis were marked.
Preparation of nuclear and cytoplasm extracts. The separation of nuclear and cytoplasm extract was conducted by use of NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific) according to the manufacturer's instructions. Briefly, cells were washed before being harvested by scrap. After treatment with cell lysis buffer on ice for 15-20 min. with intermittent mixing, cell lysis was centrifuged at 12,000 9 g at 4°C for 10 min. The supernatant was cytoplasmic extract. The pelleted nuclei were further treated with nuclear extraction buffer. After centrifugation at 12,000 9 g for 15 min. at 4°C, the nuclear proteins were collected by collecting the supernatant part.
Statistical analysis. The results were reported as mean AE S.D. of three independent experiments unless otherwise specified. The analysis was used SPSS 17.0 (SPSS Inc., Chicago, IL, USA) for Windows. Statistical significance was p < 0.05.
Results
The expressions of IL-6 and IL-8 were increased in ERÀ breast cancer. It has been reported that the expressions of IL1B, IL6, IL8 and IL10 are correlated with the poor prognosis of ERÀ breast cancer [11, 12] . Their expression was checked by use of qRT-PCR in ER+/À breast cancer cells and compared with that in normal breast epithelial cell MCF10A. Our data showed that the expressions of IL-6 and IL-8 were significantly increased in ERÀ breast cancer cells ( fig. 1A ). Both IL-6 and IL-8 are critical for the growth and metastasis of breast cancer cells [15] . We only focused on the roles of IL-6 on the progression 1C ). In addition, our data showed that the expression of IL-6 in node metastasis negative of ERÀ breast cancer was significantly (p < 0.05) lower than that in node metastasis negative ones (table 1) . These data suggested that expression of IL-6 was increased in ERÀ breast cancer cells and tissues.
IL-6 triggered the in vitro migration and invasion of ERÀ breast cancer cells.
The effects of IL-6 on the proliferation and migration of ERÀ breast cancer cells were investigated. Our data showed that IL-6 can increase the proliferation of MDA-MB-231 cells when the concentration is greater than 100 ng/ml ( fig. 2A) .
To analyse the effects of IL-6 on the migration and invasion of ERÀ breast cancer cells, 20 ng/ml of IL-6, which had no significant effect on proliferation, was used to treat the MDA-MB-231 cells. Our data showed that IL-6 can significantly increase the wound healing of MDA-MB-231 cells ( fig. 2B ). Trans-well analysis confirmed that IL-6 treatment can increase the invasion of both MDA-MB-231 and SkBr3 cells ( fig. 2C ). Western blot analysis showed that IL-6 treatment increased the expressions of MMP-2 and vimentin in a time-dependent manner in MDA-MB-231 cells ( fig. 2D ). Collectively, our data showed that IL-6 triggered the in vitro migration and invasion of ERÀ breast cancer cells. and activation [18] . Our data confirmed that IL6 treatment can increase the nuclear localization of YAP in MDA-MB-231 cells ( fig. 3C ). It was reported that CTGF and ANKRD1 are the transcriptional targets of YAP [19] . Our results confirmed that IL6 treatment can increase the mRNA expressions of CTGF and ANKRD1 in MDA-MB-231 cells ( fig. 3D ). These data suggested that IL-6 activated the YAP signals in ERÀ breast cancer cells. Mechanically, studies revealed that LATS1/2 was involved in IL-6-induced activation of YAP. Targeted inhibition of IL-6/ YAP or IL-6/IL-8 signals synergistically suppressed the invasion of ERÀ breast cancer cells. Our study confirmed that IL-6 can trigger the progression of ERÀ breast cancers. This is consistent with a previous study showing that IL-6 is one of the most critical cytokines for growth of triple-negative breast cancer [11] . Our results showed that IL-6 is increased in ERÀ breast cancer cells and tissues. IL-6 mRNA was detected only in basal-like breast carcinoma tissues, an aggressive breast carcinoma variant showing stem cell features [22, 23] . Our data revealed that IL-6 can promote the migration and invasion of ERÀ breast cancer cells at the concentration had no effect on proliferation. Furthermore, IL-6 can facilitate Trastuzumab resistance and stabilize stem cell population of breast cancer [24] and promote the epithelial-mesenchymal transition [25] . In addition, IL-6 can promote the angiogenesis and vascular modelling via through STAT3 signalling in breast cancer cells [26] . We also found that IL-8 was up-regulated in ERÀ breast cancer cells. It can synergistically increase the IL-6-induced migration of ERÀ breast cancer cells. IL-8 secretion can induce tumour proliferation, and enhance tumour cell invasion and migration [27] . In addition, a positive correlation between elevated serum IL-8 level and diminished survival rate in breast cancer patients has been observed [28] . Together with other studies, our data suggested that targeted inhibition of IL-6 and IL-8 might be helpful for the clinical treatment of ERÀ breast cancer.
Our data revealed that LATS1-mediated activation of YAP is essential for IL-6-induced progression of ERÀ breast cancer cells. Hippo signals are involved in the proliferation and migration of breast cancer [29, 30] . IL-6-induced activation of YAP is induced by the dephosphorylation of LATS1, which will lead the dephosphorylation and activation of YAP [31] . The dephosphorylation of YAP will inhibit the binding with 14-3-3 protein which leads to cytoplasmic sequestration degradation [31] . The dephosphorylated YAP will enter into nucleus and act as a transcriptional co-factor to promote expression of several growth-related genes such as CTGF, BIRC5, AREG, CYR61 and EGFR [32] . Our study revealed that targeted inhibition of YAP can suppress the migration of ERÀ breast cancer cells and synergistically increase the inhibition effects of si-IL-6. It should be noted that concentration of IL-6 used to treat cancer cells in the present study was much greater than that of self-secretion. This might be due to that IL-6 in cancer microenvironment can be generated from a diverse cell population including T cells, B cells, macrophages, monocytes, fibroblasts, endothelial cells and several tumour cells [33, 34] .
In this study, we identified that the expressions of IL-6 and IL-8 are increased in ERÀ breast cancer cells and tissues. LAST1/2-mediated activation of YAP is involved in IL-6-induced migration and invasion of ERÀ breast cancer cells. Although IL-6-induced dephosphorylation of LATS1 still needs to be studied further, our data suggested that targeted inhibition of IL-6/YAP might a novel therapeutic target for the treatment of ERÀ breast cancer.
